Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure

• Status: RECRUITING
• Trial end date: 2028-09-28

Summary

This project is a Phase 2 trial testing the safety and efficacy of treatment with Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting in patients with BCLC A HCC treated by by percutaneous ablation (PA) procedure in a curative intent.

DUMELEP is a Multicentre, Phase 2 trial

Eligible patients will receive consecutively:

1. 1 Durvalumab 1500 mg/Tremelimumab 300 mg infusion in a neoadjuvant setting

2. percutaneous ablation procedure in a curative attempt at Day 30

3. 11 monthly Durvalumab 1500 mg infusions.

4. Classical follow-up during an additional year (every 3 months)

• Phase: PHASE2

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborator: AstraZeneca
• Treatments: durvalumab; Neoadjuvant Therapy; tremelimumab